/cloudfront-us-east-2.images.arcpublishing.com/reuters/UL775QDCLNPL3JQAG2UOBJTC2Q.jpg)
Batch of BioNTech shots on the way to China German citizens will get shot; Berlin pushes for wider use Shipment comes after Scholz visit to China last month Comes as infections spike in world’s No. 2 economy BERLIN, Dec 21 (Reuters) – Berlin has sent its first batch of BioNTech (22UAy.DE) COVID-19 vaccines to China … Read more
/cloudfront-us-east-2.images.arcpublishing.com/reuters/6BNRVUXZAJONDEHOS24SD56VXM.jpg)
Dec 19 (Reuters) – Wall Street equities closed lower on Monday for a fourth straight session with Nasdaq leading declines as investors shied away from riskier bets, worried the Federal Reserve’s tightening campaign could push the U.S. economy into a recession. The three major U.S. stock indexes have been pressured since Wednesday, when Fed Chair … Read more
/cloudfront-us-east-2.images.arcpublishing.com/reuters/RHG5KA2QTNNM5BJQOOQXP4BBV4.jpg)
Weekly jobless claims rise in line with estimates Moderna, Pfizer up as FDA authorizes updated COVID boosters Exxon climbs after boosting buyback program Dec 8 (Reuters) – The S&P 500 (.SPX) closed higher on Thursday, snapping a five-session losing streak, as investors pushed the index higher after interpreting data showing a rise in weekly jobless … Read more
/cloudfront-us-east-2.images.arcpublishing.com/reuters/KSBNFLBBGROW5JWGI3XY42UZWA.jpg)
Dec 5 (Reuters) – Elon Musk’s Neuralink, a medical device company, is under federal investigation for potential animal-welfare violations amid internal staff complaints that its animal testing is being rushed, causing needless suffering and deaths, according to documents reviewed by Reuters and sources familiar with the investigation and company operations. Neuralink Corp is developing a … Read more
/cloudfront-us-east-2.images.arcpublishing.com/reuters/OWONSDP4GRPLZHGRIWIWIAYD3Y.jpg)
LONDON, Nov 16 (Reuters) – Britain’s agency that determines if medicines should be used in the National Health Service (NHS), has recommended stopping the use of five COVID-19 treatments, including Merck & Co’s (MRK.N)’s antiviral pill for high-risk patients, citing cost-effectiveness concerns. The review, conducted by the National Institute for Health and Care Excellence (NICE) … Read more
/cloudfront-us-east-2.images.arcpublishing.com/reuters/3OWHB6LJ6NLR3GE6KG7UZ5QOL4.jpg)
Trials show small benefit, but without statistical validity Roche’s setback leaves Biogen, Eisai as leaders in the field Onus on Roche CEO-designate to revive development fortunes Roche shares down 3.4%, development partner Morphosys down 29% Nov 14 (Reuters) – Roche’s (ROG.S) Alzheimer’s drug candidate could not be shown to slow dementia progression in two drug … Read more
/cloudfront-us-east-2.images.arcpublishing.com/reuters/XTYZUVICIRKRFMMJM5LC6JXQDU.jpg)
Moderna’s logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration Register now for FREE unlimited access to Reuters.com Register Aug 26 (Reuters) – Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved … Read more
/cloudfront-us-east-2.images.arcpublishing.com/reuters/TNMQAFFLVVIPRDL7LFVCRP4544.jpg)
A nurse prepares a dose of the Moderna coronavirus disease (COVID-19) vaccine at the Glangwili General Hospital in Carmarthen, Wales, Britain April 7, 2021. Jacob King/Pool via REUTERS Register now for FREE unlimited access to Reuters.com Register UK’s JCVI backs using bivalent shot in autumn booster campaign Moderna sees Australia, Canada, EU approvals soon LONDON, … Read more
/cloudfront-us-east-2.images.arcpublishing.com/reuters/CDSJUIENHNNHXC35YQHL76WSVY.jpg)
Aug 8 (Reuters) – Pfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics (GBT.O), as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment. Pfizer will pay $68.50 per GBT share, which represents a 7.3% premium to its Friday … Read more
/cloudfront-us-east-2.images.arcpublishing.com/reuters/4QAIQNUS6JK4HCW4FOSK4P4JNY.jpg)
July 14 (Reuters) – The European Medicines Agency on Thursday identified severe allergic reactions as potential side effects of Novavax Inc’s (NVAX.O) COVID-19 vaccine. The vaccine was authorized by U.S. regulators on Wednesday, and its product label in the United States warns against administering the shot to people with a history of allergic reactions to … Read more